Bio-Techne Corp (TECH) Social Stream
BIO-TECHNE CORP (TECH) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering BIO-TECHNE CORP.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-02 | 9 | $600 | $400 | $510.625 | $332.84 | 53.41% |
| 2021-12-01 | 9 | $600 | $400 | $511.875 | $332.84 | 53.79% |
| 2022-02-01 | 9 | $600 | $400 | $506.25 | $332.84 | 52.1% |
| 2022-03-01 | 6 | $600 | $540 | $565 | $332.84 | 69.75% |
| 2022-04-25 | 7 | $600 | $370 | $532.5 | $332.84 | 59.99% |
| 2022-05-05 | 7 | $575 | $370 | $515.833 | $332.84 | 54.98% |
| 2022-06-06 | 7 | $575 | $370 | $506.428 | $332.84 | 52.15% |
| 2022-08-04 | 6 | $580 | $370 | $507.142 | $332.84 | 52.37% |
| 2022-08-05 | 6 | $580 | $370 | $491.428 | $332.84 | 47.65% |
| 2022-08-16 | 6 | $580 | $360 | $490 | $332.84 | 47.22% |
The Trend in the Analyst Price Target
TECH's average price target has moved up $36.11 over the prior 15 months.
TECH reports an average of 25.82% for its upside potential over the past 49 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-01-07 | 9 | 600 | 400 | 506.250 | 415.28 | 21.91% |
| 2022-02-01 | 9 | 600 | 410 | 542.500 | 401.57 | 35.09% |
| 2022-05-05 | 7 | 575 | 370 | 513.571 | 386.15 | 33% |
| 2022-05-05 | 7 | 575 | 370 | 515.833 | 386.15 | 33.58% |
| 2022-07-14 | 6 | 580 | 370 | 507.142 | 341.39 | 48.55% |
TECH Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.67 | 5 | 0 | 0 | 1 | 1 | 6 |
The Trend in the Broker Recommendations
Over the past 30 months, TECH's average broker recommendation rating improved by 0.21.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- TECH has a greater average analyst price target than 1571.52% of all US stocks.
- TECH has a higher number of analysts covering the stock than 266.5% of stocks in the large market cap category.
- In the context of Pharmaceutical Products stocks, BIO-TECHNE CORP's variance in analysts' estimates is lower than -295.74% of them.
- BIO-TECHNE CORP's upside potential (average analyst target price relative to current price) is greater than 400.18% of Pharmaceutical Products stocks.
Stocks similar to BIO-TECHNE CORP in the Pharmaceutical Products industry regarding analyst recommendations and price targets are SGEN, RGEN, and QGEN.
View All Top Stocks by Price Target
What is the outlook for TECH? Use POWR Ratings for clearer insight into price direction.